Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057746 · ClinicalTrials.gov registry record · Phase 2
Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT00057746: Completed Phase 2 study, sponsored by Radiation Therapy Oncology Group.
NCT00057746 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 265 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057746, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in preventing brain metastases in patients with limited-stage small cell lung cancer while taking into account chronic neurotoxicity from radiation therapy. PURPOSE: This randomized phase II trial compares the incidence of chronic neurotoxicity between three different brain irradiation regimens. The corresponding phase III component addressing the prevention of brain metastases was run by EORTC and reported separately (NCT00005062).
Primary Outcome
Chronic neurotoxicity is defined as a drop in one standard error of measurement (SEM) in any one of the three tests comprising the neuropsychological test battery (Hopkins Verbal Learning Test, Controlled Word Association Test, and Trail-Making Test) without development of brain metastasis by one year. The SEM is calculated as the standard deviation of the baseline test multiplied by the square root of one minus the published reliability coefficient for the test.
Interventions
- RADIATION Prophylactic cranial irradiation, 2.5 Gy fx
- RADIATION Prophylactic cranial irradiation, 2.0 Gy fx
- RADIATION Prophylactic cranial irradiation, 1.5 Gy fx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2003-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT00057746 record still lists
NCT00057746 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% higher).
The record links to 0 conditions, and to 3 interventions - of which Prophylactic cranial irradiation, 2.5 Gy fx is the first listed.
NCT00057746 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057746 about?
NCT00057746 is a clinical study titled "Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective in preventing brain metastases in patients with limited-stage small cell lung cancer while taking into account chronic neurotoxicity from radiation therap...
What is the current status of trial NCT00057746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2003-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00057746?
The interventions under investigation include: Prophylactic cranial irradiation, 2.5 Gy fx (RADIATION), Prophylactic cranial irradiation, 2.0 Gy fx (RADIATION), Prophylactic cranial irradiation, 1.5 Gy fx (RADIATION).
Who is sponsoring clinical trial NCT00057746?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00057746's enrollment target sits among peer trials
265 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia